Browsing by Author "Sonmezer, Meliha Cagla"

Now showing 1 - 2 of 2

Burden of Pneumococcal Disease and Adult Vaccination Landscape: An Overview With Data and Policy Insights From Turkiye
(Doc Design Informatics Co Ltd, 2025) Durusu-Tanriover, Mine; Adak, Mine; Cicekcioglu, Hulya; Ozger, Hasan Selcuk; Zeren-Ozturk, Guzin; Sonmezer, Meliha Cagla; Sayiner, Abdullah
Streptococcus pneumoniae (pneumococcus) is responsible for various non-invasive and invasive infections and remains a major source of morbidity and mortality, particularly among older adults and at-risk adults. Vaccination is an effective way to prevent pneumococcal disease, and pneumococcal vaccines have been part of national immunization programs for many years. While vaccination coverage is high in children, uptake among older adults and at-risk adult populations remains below desired levels. This article aimed to highlight the burden of pneumococcal disease in adults, review current pneumococcal vaccines, and present a comprehensive overview supported by data from Turkiye.
Citation - WoS: 3
Citation - Scopus: 3
Respiratory Syncytial Virus (RSV) Infections in Adults: Current Trends and Recommendations for Prevention - a Global Challenge From a Local Perspective
(Taylor & Francis inc, 2025) Tanriover, Mine Durusu; Azap, Alpay; Cakir Edis, Ebru; Ozger, Hasan Selcuk; Pullukcu, Husnu; Sonmezer, Meliha Cagla; Sayiner, Abdullah
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTI) and a major health threat especially for children and older adults. Epidemiological data reveal that RSV-associated global mortality rates in individuals aged >= 70 years exceeded those in children aged < 5 years in 2019. Although effective interventions have decreased RSV-related deaths in children aged < 5 years over time, RSV appears increasingly significant issue for the elderly and adults with underlying health conditions. Furthermore, there is currently no specific treatment for RSV infections in adults, highlighting the importance of prevention. Recently, three vaccines (RSVPreF3, RSVpreF, and mRNA-1345) have been approved for adults to date. In this article, we aimed to review the characteristics of RSV infections in adults and the evidence on the safety and efficacy of RSV vaccines, with a glimpse of the current situation in T & uuml;rkiye- one of the low- and middle- income countries (LMICs).